Investigational dopamine antagonists for the treatment of schizophrenia

References

• Evensen S, Wisloff T, Lystad JU, et al. Prevalence, employment rate, and cost of schizophrenia in a high-income welfare society: a population-based study using comprehensive health and welfare registers. Schizophr Bull. 2016;42:476–483.
   PubMed Web of Science ®Google Scholar
• Pae CU, Juh R, Yoo SS, et al. Verbal working memory dysfunction in schizophrenia: an fmri investigation. Int J Neurosci. 2008;118:1467–1487.
   PubMed Web of Science ®Google Scholar
• Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010;71:1115–1124.
   PubMed Web of Science ®Google Scholar
• Elkis H, Buckley PF. Treatment-resistant schizophrenia. Psychiatr Clin North Am. 2016;39:239–265.
   PubMed Web of Science ®Google Scholar
• Reynolds GP. Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia. Acta Psychiatr Scand Suppl. 1994;380:36–40.
   PubMedGoogle Scholar
• Hu W, MacDonald ML, Elswick DE, et al. The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann N Y Acad Sci. 2015;1338:38–57.
   PubMed Web of Science ®Google Scholar
• Eggers AE. A serotonin hypothesis of schizophrenia. Med Hypotheses. 2013;80:791–794.
   PubMed Web of Science ®Google Scholar
• Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321:1371–1376.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Papanastasiou E, Stahl D, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41:892–899.
   PubMed Web of Science ®Google Scholar
• Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414–425.
   PubMed Web of Science ®Google Scholar
• Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765–1773.
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Gil R, Krystal J, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry. 1998;155:761–767.
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi-Dargham A, van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA. 1996;93:9235–9240.
   PubMed Web of Science ®Google Scholar
• Byne W, Davis KL. The role of prefrontal cortex in the dopaminergic dysregulation of schizophrenia. Biol Psychiatry. 1999;45:657–659.
   PubMed Web of Science ®Google Scholar
• Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version iii–the final common pathway. Schizophr Bull. 2009;35:549–562.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Buchanan RW, Ross DE, et al. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58:165–171.
   PubMed Web of Science ®Google Scholar
• Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005;10:40–68. image 5.
   PubMed Web of Science ®Google Scholar
• Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006;26:365–384.
   PubMed Web of Science ®Google Scholar
• Zink M, Correll CU. Glutamatergic agents for schizophrenia: current evidence and perspectives. Expert Rev Clin Pharmacol. 2015;8:335–352.
   PubMed Web of Science ®Google Scholar
• Levkovitz Y, Levi U, Braw Y, et al. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res. 2007;1154:154–162.
   PubMed Web of Science ®Google Scholar
• Fond G, Hamdani N, Kapczinski F, et al. Effectiveness and tolerance of anti-inflammatory drugs’ add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand. 2014;129:163–179.
   PubMed Web of Science ®Google Scholar
• Jones CK, Byun N, Bubser M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology. 2012;37:16–42.
   PubMed Web of Science ®Google Scholar
• Kehler J, Nielsen J. Pde10a inhibitors: novel therapeutic drugs for schizophrenia. Curr Pharm Des. 2011;17:137–150.
   PubMed Web of Science ®Google Scholar
• Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94.
   PubMed Web of Science ®Google Scholar
• McLeod MC, Scarr E, Dean B. Effects of benzodiazepine treatment on cortical gaba(a) and muscarinic receptors: studies in schizophrenia and rats. Psychiatry Res. 2010;179:139–146.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Elkis H, Vanover K, et al. Pimavanserin, a selective serotonin (5-ht)2a-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr Res. 2012;141:144–152.
   PubMed Web of Science ®Google Scholar
• Wang SM, Han C, Lee SJ, et al. Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics. Clin Neuropharmacol. 2013;36:223–238.
   PubMed Web of Science ®Google Scholar
• Insel TR. Rethinking schizophrenia. Nature. 2010;468:187–193.
   PubMed Web of Science ®Google Scholar
• Greig SL. Brexpiprazole: first global approval. Drugs. 2015;75:1687–1697.
   PubMed Web of Science ®Google Scholar
• Citrome L. Cariprazine for the treatment of schizophrenia: a review of this dopamine d3-preferring d3/d2 receptor partial agonist. Clin Schizophr Relat Psychoses. 2016;10:109–119.
   PubMedGoogle Scholar
• Redden L, Rendenbach-Mueller B, Abi-Saab WM, et al. A double-blind, randomized, placebo-controlled study of the dopamine d(3) receptor antagonist abt-925 in patients with acute schizophrenia. J Clin Psychopharmacol. 2011;31:221–225.
   PubMed Web of Science ®Google Scholar
• Gross G, Wicke K, Drescher KU. Dopamine d(3) receptor antagonism–still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:155–166.
   PubMed Web of Science ®Google Scholar
• Graff-Guerrero A, Redden L, Abi-Saab W, et al. Blockade of [11c](+)-phno binding in human subjects by the dopamine d3 receptor antagonist abt-925. Int J Neuropsychopharmacol. 2010;13:273–287.
   PubMed Web of Science ®Google Scholar
• Bhathena A, Wang Y, Kraft JB, et al. Association of dopamine-related genetic loci to dopamine d3 receptor antagonist abt-925 clinical response. Transl Psychiatry. 2013;3:e245.
   Google Scholar
• Fitzgerald PB. BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia. Curr Opin Investig Drugs. 2010;11:92–100.
   PubMedGoogle Scholar
• Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr Res. 2009;110:1–23.
   PubMed Web of Science ®Google Scholar
• Bhoopathi PS, Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2006;19(3):CD000205.
   Google Scholar
• Geffen Y, Nudelman A, Gil-Ad I, et al. Bl-1020: a novel antipsychotic drug with gabaergic activity and low catalepsy, is efficacious in a rat model of schizophrenia: European neuropsychopharmacology. Journal Eur Coll Neuropsychopharmacol. 2009;19:1–13.
   PubMed Web of Science ®Google Scholar
• Nudelman A, Gil-Ad I, Shpaisman N, et al. A mutual prodrug ester of gaba and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects. J Med Chem. 2008;51:2858–2862.
   PubMed Web of Science ®Google Scholar
• Uehara T, Sumiyoshi T, Kurachi M. New pharmacotherapy targeting cognitive dysfunction of schizophrenia via modulation of gaba neuronal function. Curr Neuropharmacol. 2015;13:793–801.
   PubMed Web of Science ®Google Scholar
• Geffen Y, Keefe R, Rabinowitz J, et al. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. J Clin Psychiatry. 2012;73:e1168–74.
   PubMedGoogle Scholar
• Nct01363349. Phase iib-iii study of bl-1020 small molecule for schizophrenia (clarity): clinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT01363349?term=NCT±01363349&rank=1
   Google Scholar
• The MATRICS Consensus Cognitive Battery (MCCB). [cited 2017 Jan 2]. Available from: www.matricsinc.org
   Google Scholar
• BioLineRx Announces Results from Interim Analysis of Phase II/III CLARITY Trial of BL-1020 for Schizophrenia. Press release 23 Mar 2013. [cited 2017 Jan 2. Available from: https://www.Biolinerx.Com/default.Asp?Pageid=16&itemid=180
   Google Scholar
• Appel L, Geffen Y, Heurling K, et al. Bl-1020, a novel antipsychotic candidate with gaba-enhancing effects: D2 receptor occupancy study in humans: European neuropsychopharmacology. Journal Eur Coll Neuropsychopharmacol. 2009;19:841–850.
   PubMed Web of Science ®Google Scholar
• NCT00480571. Safety and Tolerability of BL-1020 in hospitalized subjects with chronic schizophrenia or schizo-affective disorder. [cited 2017 Jan 2. Available from: clinicaltrials.Gov/ct2/show/nct00480571?Term=bl+1020&rank=1
   Google Scholar
• NCT00722176. Extension study to evaluate the long-term safety, tolerability, and efficacy of low and high doses of Bl-1020. [cited 2017 Jan 2]. Available from: clinicaltrials.Gov/ct2/show/nct00722176?Term=bl+1020&rank=2
   Google Scholar
• Davis RE, Correll CU. Iti-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. Expert Rev Neurother. 2016;16:601–614.
   PubMed Web of Science ®Google Scholar
• Snyder GL, Vanover KE, Zhu H, et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology (Berl). 2015;232:605–621.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Davis RE, Correll CU, et al. Iti-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry. 2016;79:952–961.
   PubMed Web of Science ®Google Scholar
• Vanover KE, Davis RE, O’Gorman C, et al. Clinical development of iti-007 for the treatment of schizophrenia. Neuropsychopharmacology. 2015; 40(S1–W166);S548–549.
   Google Scholar
• Citrome L. Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next? CNS Spectr. 2016;21:1–12.
   PubMed Web of Science ®Google Scholar
• Intra-cellular therapies. Corporate presentation, 2016. [cited 2017 Jan 2. Available from: https://files.Shareholder.Com/downloads/amda-2o83fw/2571108091x0x862131/df51c35d-c947-4959-b5a6-dc4b9bc3cf76/itci_corporate_presentation.Pdf
   Google Scholar
• te Beek ET, Moerland M, de Boer P, et al. Pharmacokinetics and central nervous system effects of the novel dopamine d2 receptor antagonist jnj-37822681. J Psychopharmacol. 2012;26:1119–1127.
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry. 2001;158:360–369.
   PubMed Web of Science ®Google Scholar
• Seeman P. An update of fast-off dopamine d2 atypical antipsychotics. Am J Psychiatry. 2005;162:1984–1985.
   PubMed Web of Science ®Google Scholar
• Schmidt ME, Kent JM, Daly E, et al. A double-blind, randomized, placebo-controlled study with jnj-37822681, a novel, highly selective, fast dissociating d(2) receptor antagonist in the treatment of acute exacerbation of schizophrenia: European neuropsychopharmacology. J Eur Coll Neuropsychopharmacol. 2012;22:721–733.
   PubMed Web of Science ®Google Scholar
• Daly EJ, Kent JM, Janssens L, et al. Metabolic and body mass parameters after treatment with jnj-37822681, a novel fast-dissociating d2 receptor antagonist, vs olanzapine in patients with schizophrenia. Ann Clin Psychiatry. 2013;25:173–183.
   PubMed Web of Science ®Google Scholar
• Sutin EL, Jacobowitz DM. Neurochemicals in the dorsal pontine tegmentum. Prog Brain Res. 1991;88:3–14.
   PubMed Web of Science ®Google Scholar
• Yun J. L-tetrahydropalmatine inhibits methamphetamine-induced locomotor activity via regulation of 5-ht neuronal activity and dopamine d3 receptor expression. Phytomedicine. 2014;21:1287–1291.
   PubMed Web of Science ®Google Scholar
• Xu W, Wang Y, Ma Z, et al. L-isocorypalmine reduces behavioral sensitization and rewarding effects of cocaine in mice by acting on dopamine receptors. Drug Alcohol Depend. 2013;133:693–703.
   PubMed Web of Science ®Google Scholar
• Hassan HE, Kelly D, Honick M, et al. Pharmacokinetics and safety assessment of l-tetrahydropalmatine in cocaine users: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 2017;57(2):151–160.
   PubMed Web of Science ®Google Scholar
• Yu M, Hassan HE, Ibrahim A, et al. Simultaneous determination of l-tetrahydropalmatine and cocaine in human plasma by simple uplc-fld method: application in clinical studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;965:39–44.
   PubMed Web of Science ®Google Scholar
• NCT02118610. Treatment of schizophrenia with l-tetrahydropalmatine (l-thp). A novel dopamine antagonist with anti-inflammatory and antiprotozoal activity. [cited 2017 Jan 2. Available from: http://clinicaltrials.Gov/ct2/show/nct02118610?Term=l-tetrahydropalmatine&rank=1
   Google Scholar
• Rao NP, Remington G. Investigational drugs for schizophrenia targeting the dopamine receptor: phase ii trials. Expert Opin Investig Drugs. 2013;22:881–894.
   PubMed Web of Science ®Google Scholar
• Lundbeck Corporate Release. 5 Feb 2015. Performance in 2014 positions lundbeck well for 2015 and beyond. [cited 2017 Jan 2. Available from: http://files.shareholder.com/downloads/AMDA-GGC00/2639699771x0x807211/98C06E75-E43A-476B-BEE1-940056FC8CFF/Lundbeck_FY2014_Results.pdf
   Google Scholar
• Lundbeck Corporate Release Valby, 11 May 2016. Lundbeck starts clinical phase iii program with lu af35700 in patients with treatment resistant schizophrenia. [cited 2017 Jan 2]. Available from: http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=960101
   Google Scholar
• NCT02202226. Safety and tolerability study of lu af35700 after repeated dosing in patients with schizophrenia. [cited 2017 Jan 2. Avaialble from: http://clinicaltrials.Gov/ct2/show/nct02202226?Term=lu+af35700&rank=4
   Google Scholar
• NCT02901587. Study investigating the effect of lu af35700 on cardiac repolarization in men and women with schizophrenia and schizoaffective disorder. [cited 2017 Jan 2]. Available from https://clinicaltrials.Gov/ct2/show/nct02901587?Term=lu+af35700&rank=5
   Google Scholar
• NNT02717195. Effect of lu af35700 in patients with treatment-resistant schizophrenia. [cited 2017 Jan 2]. Available from: https://clinicaltrials.Gov/ct2/show/nct02717195?Term=lu+af35700&rank=6
   Google Scholar
• Millan MJ, Loiseau F, Dekeyne A, et al. S33138 (n-[4-[2-[(3as,9br)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3h)-yl)-ethyl]phenyl-acetamide), a preferential dopamine d3 versus d2 receptor antagonist and potential antipsychotic agent: iii. Actions in models of therapeutic activity and induction of side effects. J Pharmacol Exp Ther. 2008;324:1212–1226.
   PubMed Web of Science ®Google Scholar
• Millan MJ, Buccafusco JJ, Loiseau F, et al. The dopamine d3 receptor antagonist, s33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol. 2010;13:1035–1051.
   PubMed Web of Science ®Google Scholar
• Catafau AM, Bullich S, Nucci G, et al. Contribution of spect measurements of d2 and 5-ht2a occupancy to the clinical development of the antipsychotic sb-773812. J Nucl Med. 2011;52:526–534.
   PubMed Web of Science ®Google Scholar
• NCT00500201. A healthy volunteer study to assess the relative bioavailability of 2 forms of sb773812 tablets. [cited 2017 Jan 2. Available from: https://clinicaltrials.Gov/ct2/show/nct00500201?Term=sb-773812&rank=4
   Google Scholar
• NCT00197093. In-patient study in schizophrenic patients. [cited 2017 Jan 2]. Available from: https://clinicaltrials.Gov/ct2/show/nct00197093?Term=sb-773812&rank=5
   Google Scholar
• Green MF. Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. J Clin Psychiatry. 2016;77(Suppl 2):8–11.
   PubMed Web of Science ®Google Scholar
• Nandra KS, Agius M. The differences between typical and atypical antipsychotics: the effects on neurogenesis. Psychiatr Danub. 2012;24(Suppl 1):S95–9.
   PubMed Web of Science ®Google Scholar
• Koster LS, Carbon M, Correll CU. Emerging drugs for schizophrenia: an update. Expert Opin Emerg Drugs. 2014;19:511–531.
   PubMed Web of Science ®Google Scholar
• Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151:1409–1416.
   PubMed Web of Science ®Google Scholar
• Rao NP, Remington G. Targeting the dopamine receptor in schizophrenia: investigational drugs in phase iii trials. Expert Opin Pharmacother. 2014;15:373–383.
   PubMed Web of Science ®Google Scholar
• Brisch R, Saniotis A, Wolf R, et al. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry. 2014;5:47.
   PubMed Web of Science ®Google Scholar
• Sershen H, Balla A, Aspromonte JM, et al. Characterization of interactions between phencyclidine and amphetamine in rodent prefrontal cortex and striatum: implications in nmda/glycine-site-mediated dopaminergic dysregulation and dopamine transporter function. Neurochem Int. 2008;52:119–129.
   PubMed Web of Science ®Google Scholar
• Scatton B, Claustre Y, Cudennec A, et al. Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol. 1997;12(Suppl 2):S29–36.
   Web of Science ®Google Scholar
• McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs. 2004;18:933–956.
   PubMed Web of Science ®Google Scholar
• Sokoloff P, Le Foll B. The dopamine d3 receptor, a quarter century later. Eur J Neurosci. 2017;45:2–19.
   PubMed Web of Science ®Google Scholar
• Davis RE, Vanover KE, Zhou Y, et al. Iti-007 demonstrates brain occupancy at serotonin 5-ht(2)a and dopamine d(2) receptors and serotonin transporters using positron emission tomography in healthy volunteers. Psychopharmacology (Berl). 2015;232:2863–2872.
   PubMed Web of Science ®Google Scholar
• Naumovska Z, Nestorovska AK, Filipce A, et al. Pharmacogenetics and antipsychotic treatment response. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015;36:53–67.
   PubMedGoogle Scholar
• Xu Q, Wu X, Xiong Y, et al. Pharmacogenomics can improve antipsychotic treatment in schizophrenia. Front Med. 2013;7:180–190.
   PubMed Web of Science ®Google Scholar